PneuX: a pneumonia prevention system designed to stop ventilator-associated pneumonia.

Challenge/problem identified

Ventilator-associated pneumonia (VAP) is the leading cause of infective hospital-acquired mortality, affecting up to 20,000 patients per year and causing almost a third of those affected to die. Each episode costs the NHS between £10,000 and £20,000. Standard endotracheal tubes allow the leakage of bacteria contaminated secretions from the mouth and stomach contents, past the endotracheal tube cuff and into the patient’s lungs, leading to VAP.

The solution

Pneux is a cuffed ventilation tube and electronic cuff pressure monitor and controller designed to stop leakage of pathogenic oral secretions and stomach contents into the lungs, preventing ventilator-associated pneumonia (VAP).

Unlike standard ventilation tubes, PneuX has a cuff which achieves an effective seal inside the patient’s trachea, which prevents leakage or aspiration of bacteria- contaminated secretions into the lungs. The cuff pressure monitor continuously measures pressure and ensures the seal remains effective at all times, even when the patient coughs or moves. PneuX can be used in any patient requiring mechanical ventilation in the Intensive Care Unit (ICU), emergency department or for patients undergoing major surgery in operating theatres.

Impact

  • An independent health economic evaluation by the University of Birmingham and the Royal College of Surgeons, based on an NHS England funded patient study at New Cross Hospital, showed that using the PneuX has a cost saving to the NHS of £718 for every patient, when introduced into the ICU.
  • PneuX shows zero leakage of bacteria, compared with other endotracheal tube cuffs on the market, each of which show a degree of leakage.
  • Available to procure at zero cost via the 2017-19 Innovation and Technology Tariff.

Find out more

For more information, please contact: n.dill@qualitechhealthcare.co.uk

www.klipsuk.com

A randomised controlled study shows that PneuX prevents VAP. Read the paper here: www.ncbi.nlm.nih.gov/pubmed/25542910

One study highlighted that 50% of all antibiotics used in the ICU are to treat VAP. The review article noting this can be seen here: www.ccforum.biomedcentral.com/articles/10.1186/cc13775